Check for updates

OPEN ACCESS

EDITED AND REVIEWED BY Olivier Feron, Université Catholique de Louvain, Belgium

*CORRESPONDENCE Zhaoshi Bai, ⊠ zhaoshi_bai@njmu.edu.cn

RECEIVED 09 September 2023 ACCEPTED 18 September 2023 PUBLISHED 27 September 2023

CITATION

Bai Z, Dou J, Saleh T, Xu J and Zhu W (2023), Editorial: Different cell death modes in cancer treatment. *Front. Pharmacol.* 14:1291585. doi: 10.3389/fphar.2023.1291585

COPYRIGHT

© 2023 Bai, Dou, Saleh, Xu and Zhu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Editorial: Different cell death modes in cancer treatment

Zhaoshi Bai¹*, Jie Dou², Tareq Saleh³, Jingwen Xu⁴ and Wufu Zhu⁵

¹Jiangsu Cancer Hospital and Jiangsu Institute of Cancer Research and the Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, Jiangsu, China, ²School of Life Science and Technology, China Pharmaceutical University, Nanjing, Jiangsu, China, ³Department of Pharmacology and Public Health, Faculty of Medicine, The Hashemite University, Zarqa, Jordan, ⁴Guangdong Pharmaceutical University, Guangzhou, China, ⁵Jiangxi Science and Technology Normal University, Nanchang, China

KEYWORDS

cell death modes, mechanism, interaction, anticancer drugs, drug discovery

Editorial on the Research Topic

Different cell death modes in cancer treatment

Anticancer drugs exert effects by inducing various types of cell death, including apoptosis, necroptosis, ferroptosis, pyroptosis, parthanatos, entotic cell death, autophagy, cellular senescence, and mitotic catastrophe (Galluzzi et al., 2018; Wang et al., 2022). These cell death modes are usually not presented separately, resulting in the complex interactions (including synergistic, complementary, additive, even competitive or antagonistic effects) among them during cancer treatment (Qi et al., 2022; Zhao et al., 2022). Therefore, in-depth understanding of the molecular mechanisms underlying drug-induced different cell death modes and the interactions among these cell death modes, has a positive significance for the research and development of new anticancer drugs and treatment, we attempted to collect the most-recent progress made in cell death modes in cancer treatment. In total, after being peer-reviewed, seven manuscripts, composed with four research articles and three review articles authored by 49 researchers worldwide, were successfully accepted for publication.

Currently, most drugs are able to exert potent anticancer effects by inducing apoptosis (Nossing and Ryan, 2022). Chen et al. reported that Yiwei decoction (YWD), a traditional Chinese medicine (TCM) formula, can promote apoptosis of gastric cancer cells through spleen-derived exosomes, thereby supporting the use of YWD-treated exosomes as a new approach for the clinical treatment of gastric cancer. However, due to the fact that apoptosis is usually codetermined by dozens of proapoptotic and antiapoptotic genes/proteins, multidrug resistance (MDR) mediated by apoptosis resistance is more common than that mediated by other factors (Bueschbell et al., 2022). Thus, it is very attractive to avoid the apoptosis resistance pathway by inducing non-apoptotic cell death modes. Yang et al. reviewed the current status of research on the molecular mechanisms and targets through quercetin-mediated non-apoptotic mode of cancer cell death. Autophagy is a lysosome-mediated catabolic process of cell adaptation to metabolic and environmental stress and plays a complex effect in cancer treatment (Manzoor et al., 2022). Zhang et al. reviewed the roles and underlying mechanisms of Tripartite motif (TRIM) family proteins in tumorigenesis and progression. Further, they pointed out that TRIMs may be the core components of autophagy or part of the autophagyinduced pathway in cancer treatment. Paraptosis is an alternative cell death pathway characterized by vacuolation and damage to the endoplasmic reticulum and mitochondria (Hanson et al.). Hanson et al. presented a systematic review of the growth, challenges, and

future perspectives of paraptosis research in cancer treatment, which will help to develop potential therapy and combat chemoresistance in various cancer. Cuproptosis, a newly defined regulation form of cell death, is mediated by the accumulation of copper ions in cells and related to protein lipoacylation (Hadian and Stockwell, 2023; Wu et al. , 2023). Ma et al. found that an eight-lncRNA signature (TSPOAP1-AS1, AC107464.3, AC006449.7, LINC00324, COLCA1, HAGLR, MIR4435-2HG, and NKILA) linked to cuproptosis was identified, which may improve lung adenocarcinoma management strategies. Xu et al. reported that cuproptosis-related prognostic 2-lncRNAs signature (BCCuS) may be useful in predicting the prognosis, biological characteristics, and appropriate treatment of breast cancer patients. In addition, the induction of immunogenic cancer cell death has become one of the aims of drugs because it would allow the immune system to contribute through a "bystander effect" to the eradication of therapy-resistant cancer cells and cancer stem cells (Kroemer et al., 2022). Based on a bibliometric analysis, Zhou et al. provided an intuitive approach to investigate the research trends and hotspots concerning immunogenic cell death in cancer treatment.

In conclusion, an increasing number of cell death modes have attracted attention in recent years. Each cell death mode has unique advantages and disadvantages, and fully utilizing their advantages and avoiding their disadvantages has positive significance in cancer treatment.

References

Bueschbell, B., Caniceiro, A. B., Suzano, P. M. S., Machuqueiro, M., Rosario-Ferreira, N., and Moreira, I. S. (2022). Network biology and artificial intelligence drive the understanding of the multidrug resistance phenotype in cancer. *Drug Resist Updat* 60, 100811. doi:10.1016/j.drup.2022.100811

Galluzzi, L., Vitale, I., Aaronson, S. A., Abrams, J. M., Adam, D., Agostinis, P., et al. (2018). Molecular mechanisms of cell death: recommendations of the nomenclature committee on cell death 2018. *Cell Death Differ*. 25, 486–541. doi:10.1038/s41418-017-0012-4

Hadian, K., and Stockwell, B. R. (2023). The therapeutic potential of targeting regulated non-apoptotic cell death. *Nat. Rev. Drug Discov.* 22, 723–742. doi:10.1038/ s41573-023-00749-8

Kroemer, G., Galassi, C., Zitvogel, L., and Galluzzi, L. (2022). Immunogenic cell stress and death. *Nat. Immunol.* 23, 487–500. doi:10.1038/s41590-022-01132-2

Manzoor, S., Muhammad, J. S., Maghazachi, A. A., and Hamid, Q. (2022). Autophagy: a versatile player in the progression of colorectal cancer and drug resistance. *Front. Oncol.* 12, 924290. doi:10.3389/fonc.2022.924290

Author contributions

ZB: Conceptualization, Writing-original draft, Writing-review and editing. JD: Conceptualization, Writing-review and editing. TS: Conceptualization, Writing-review and editing. JX: Conceptualization, Writing-review and editing. WZ: Conceptualization, Writing-review and editing.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Nossing, C., and Ryan, K. M. (2022). 50 years on and still very much alive: apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. *Br. J. Cancer* 128, 426–431. doi:10.1038/s41416-022-02020-0

Qi, X., Jiang, L., and Cao, J. (2022). Senotherapies: a novel strategy for synergistic anti-tumor therapy. *Drug Discov. Today* 27, 103365. doi:10.1016/j.drudis.2022. 103365

Wang, X., Hua, P., He, C., and Chen, M. (2022). Non-apoptotic cell death-based cancer therapy: molecular mechanism, pharmacological modulators, and nanomedicine. *Acta Pharm. Sin. B* 12, 3567–3593. doi:10.1016/j.apsb.2022.03.020

Wu, Z., Lv, G., Xing, F., Xiang, W., Ma, Y., Feng, Q., et al. (2023). Copper in hepatocellular carcinoma: a double-edged sword with therapeutic potentials. *Cancer Lett.* 571, 216348. doi:10.1016/j.canlet.2023.216348

Zhao, S., Tang, Y., Wang, R., and Najafi, M. (2022). Mechanisms of cancer cell death induction by paclitaxel: an updated review. *Apoptosis* 27, 647–667. doi:10.1007/s10495-022-01750-z